Cargando…

Long‐term strength and functional status in inclusion body myositis and identification of trajectory subgroups

INTRODUCTION: Objective information on longitudinal disease progression in inclusion body myositis (IBM) is lacking. METHODS: Longitudinal dynamometry and functional status data were collated from a cohort of IBM patients. Annual change was calculated by means of linear modeling. Trajectories of cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oldroyd, Alexander G. S., Lilleker, James B., Williams, Jacob, Chinoy, Hector, Miller, James A. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629114/ https://www.ncbi.nlm.nih.gov/pubmed/32134516 http://dx.doi.org/10.1002/mus.26859

Ejemplares similares

Genetics in inclusion body myositis
por: Rothwell, Simon, et al.
Publicado: (2017)

[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
por: Lilleker, James B, et al.
Publicado: (2019)

Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria
por: To, Fergus, et al.
Publicado: (2019)

Patient-centred standards of care for adults with myositis
por: Lilleker, James B., et al.
Publicado: (2017)

Mitochondrial and inflammatory changes in sporadic inclusion body myositis
por: Rygiel, Karolina A., et al.
Publicado: (2015)

Immune‐Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA–DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum
por: Rothwell, Simon, et al.
Publicado: (2017)

Update in inclusion body myositis
por: Machado, Pedro, et al.
Publicado: (2013)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis
por: Lilleker, J B, et al.
Publicado: (2017)

Detecting dysphagia in inclusion body myositis
por: Cox, F. M., et al.
Publicado: (2009)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis
por: Parkes, Joanna E., et al.
Publicado: (2018)

The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
por: Edigin, Ehizogie, et al.
Publicado: (2020)

Inclusion body myositis--a case report.
por: Park, S. H., et al.
Publicado: (1996)

Inclusion-Body Myositis Associated with Alzheimer's Disease
por: Levacic, Danijela, et al.
Publicado: (2013)

Inclusion body myositis associated with Sjögren’s syndrome
por: Misterska-Skóra, Maria, et al.
Publicado: (2012)

Proteomic study of sporadic inclusion body myositis
por: Li, Ke, et al.
Publicado: (2014)

Ongoing Developments in Sporadic Inclusion Body Myositis
por: Machado, Pedro M., et al.
Publicado: (2014)

17. Inclusion body myositis associated with SLE
por: Jones, Catrin M, et al.
Publicado: (2018)

Immune and myodegenerative pathomechanisms in inclusion body myositis
por: Keller, Christian W., et al.
Publicado: (2017)

Survival and associated comorbidities in inclusion body myositis
por: Naddaf, Elie, et al.
Publicado: (2021)

Dysphagia as the Presenting Symptom for Inclusion Body Myositis
por: Esteban, Marcus Juan, et al.
Publicado: (2021)

Applying Hickam’s dictum: a case of adult-onset LGMD2I muscular dystrophy and long QT syndrome
por: Sheikh, Ali S F, et al.
Publicado: (2023)

Sporadic inclusion body myositis: the genetic contributions to the pathogenesis
por: Gang, Qiang, et al.
Publicado: (2014)

Emerging therapeutic options for sporadic inclusion body myositis
por: Alfano, Lindsay N, et al.
Publicado: (2015)

Inclusion body myositis – pathomechanism and lessons from genetics
por: Murnyák, Balázs, et al.
Publicado: (2015)

Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis
por: de Camargo, Leonardo Valente, et al.
Publicado: (2018)

CYLD dysregulation in pathogenesis of sporadic inclusion body myositis
por: Yamashita, Satoshi, et al.
Publicado: (2019)

Inclusion body myositis in a patient with rheumatoid arthritis
por: Tariq, Mohammad, et al.
Publicado: (2018)

Sarcoidosis: Is It a Possible Trigger of Inclusion Body Myositis?
por: Zakaria, Ali, et al.
Publicado: (2017)

Beevor’s sign in a case of inclusion body myositis
por: Sarraf, Payam, et al.
Publicado: (2021)

Inclusion body myositis: Update on the diagnostic and therapeutic landscape
por: Naddaf, Elie
Publicado: (2022)

Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis
por: Lindgren, Ulrika, et al.
Publicado: (2022)

Inclusion Body Myositis and Neoplasia: A Narrative Review
por: Damian, Laura, et al.
Publicado: (2022)

COVID-19-Induced Sporadic Inclusion Body Myositis
por: Dalal, Fazal, et al.
Publicado: (2022)

Inclusion body myositis: from genetics to clinical trials
por: Nagy, Sara, et al.
Publicado: (2022)

Correction to: Survival and associated comorbidities in inclusion body myositis
Publicado: (2022)

Exploring challenges in the management and treatment of inclusion body myositis
por: Skolka, Michael P., et al.
Publicado: (2023)

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2009)

Morphological and molecular comparison of HIV-associated and sporadic inclusion body myositis
por: Vogt, Sinja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h3n6bhg3dmmh1m6g729dn82j7h